DE60032486D1 - Prion protein peptide und deren verwendung - Google Patents

Prion protein peptide und deren verwendung

Info

Publication number
DE60032486D1
DE60032486D1 DE60032486T DE60032486T DE60032486D1 DE 60032486 D1 DE60032486 D1 DE 60032486D1 DE 60032486 T DE60032486 T DE 60032486T DE 60032486 T DE60032486 T DE 60032486T DE 60032486 D1 DE60032486 D1 DE 60032486D1
Authority
DE
Germany
Prior art keywords
prion protein
protein peptides
prp
therapeutic
antibodies specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60032486T
Other languages
English (en)
Other versions
DE60032486T2 (de
Inventor
R Cashman
Eustache Paramithiotis
Jacek Slon-Usakiewicz
Ashkan Haghighat
Marc Pinard
Trebor Lawton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Caprion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22492135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60032486(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Caprion Pharmaceuticals Inc filed Critical Caprion Pharmaceuticals Inc
Publication of DE60032486D1 publication Critical patent/DE60032486D1/de
Application granted granted Critical
Publication of DE60032486T2 publication Critical patent/DE60032486T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60032486T 1999-06-23 2000-06-23 Prion protein peptide und deren verwendung Expired - Lifetime DE60032486T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14063499P 1999-06-23 1999-06-23
US140634P 1999-06-23
PCT/US2000/017455 WO2000078344A1 (en) 1999-06-23 2000-06-23 Prion protein peptides and uses thereof

Publications (2)

Publication Number Publication Date
DE60032486D1 true DE60032486D1 (de) 2007-02-01
DE60032486T2 DE60032486T2 (de) 2007-08-16

Family

ID=22492135

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032486T Expired - Lifetime DE60032486T2 (de) 1999-06-23 2000-06-23 Prion protein peptide und deren verwendung

Country Status (12)

Country Link
EP (1) EP1194164B8 (de)
JP (1) JP2003521477A (de)
CN (1) CN1370078A (de)
AT (1) ATE348632T1 (de)
AU (1) AU783484B2 (de)
CA (1) CA2377648A1 (de)
DE (1) DE60032486T2 (de)
ES (1) ES2278617T3 (de)
HK (1) HK1048955A1 (de)
MX (1) MXPA01013186A (de)
NZ (1) NZ516240A (de)
WO (1) WO2000078344A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
BR0111975A (pt) * 2000-06-26 2003-07-01 Universitot Zuerich Fator, composição, veìculo, ligando, kits de diagnósticos, processos para detectar uma prpsc em uma amostra, e para remover prpsc de material biológico, método para diagnosticar encefalopatias espongiformes humanas transmissìveis e encefalopatias de prìons de animais, e, uso de um fator
US7303907B2 (en) 2001-01-08 2007-12-04 Health Protection Agency Degradation and detection of TSE infectivity
GB2376071A (en) * 2001-05-31 2002-12-04 Mini Agriculture & Fisheries Method for typing a TSE strain
GB2379737A (en) * 2001-09-05 2003-03-19 Univ Geneve Diagnostic method for spongiform encephalopathy disease
WO2003040685A2 (en) * 2001-11-09 2003-05-15 King's College London Diagnosis demyelinating or spongiform disease
AU2003205623A1 (en) * 2002-01-18 2003-07-30 Cytos Biotechnology Ag Prion protein carrier-conjugates
JP4421900B2 (ja) 2002-04-09 2010-02-24 ザ スクリップス リサーチ インスティテュート モチーフ・グラフトされたハイブリッドポリペプチドおよびその使用
EP1382971A1 (de) * 2002-07-17 2004-01-21 Pepscan Systems B.V. Nachweis von Prion Erkrankung
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
CA2502198A1 (en) * 2002-10-30 2004-05-13 Proteome Sciences Plc Diagnostic method for transmissible spongiform encephalopathies (prion diseases)
GB0227886D0 (en) * 2002-11-29 2003-01-08 Medical Res Council Prion inhibition
US7863411B2 (en) * 2002-12-03 2011-01-04 Pathogen Removal and Diagnostics Technologies Inc. Prion protein ligands and methods of use
CN1297663C (zh) * 2003-05-07 2007-01-31 中国科学院微生物研究所 一类重组基因产生的朊蛋白（PrPC）融合变构体及其用途
DK1653844T3 (da) 2003-08-13 2013-03-11 Novartis Vaccines & Diagnostic Prionspecifikke peptidreagenser
US20070003977A1 (en) * 2003-08-20 2007-01-04 Amorfix Life Sciences Ltd Epitope protection assay and method for detecting protein conformations
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
AU2005209592B2 (en) 2004-09-30 2012-07-12 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
US7482172B2 (en) 2005-09-19 2009-01-27 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
EP2383281A3 (de) 2005-09-09 2012-01-04 Novartis AG Prionspezifische Peptoidreagenzien
US7887803B2 (en) 2005-12-02 2011-02-15 Amorfix Life Sciences Methods and compositions to treat misfolded-SOD1 mediated diseases
US7794692B2 (en) 2005-12-02 2010-09-14 Amorfix Life Sciences Ltd. Methods and compositions for detecting amyotrophic lateral sclerosis
EP2495327B1 (de) 2006-03-03 2016-09-28 ProMIS Neurosciences Inc. Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen
US7601506B2 (en) * 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
US9056918B2 (en) 2008-04-25 2015-06-16 University Of Saskatchewan Prion epitopes and methods of use thereof
EP2128618A1 (de) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. Verfahren zur Kontrolle der Präsenz von pathogenen Wirkstoffen in biologischen Flüssigkeiten durch nanostrukturierte Stoffe
EP2342220B1 (de) * 2008-10-06 2021-05-12 The University Of British Columbia Verfahren und systeme zur vorhersage missgefalteter proteinepitope
AU2010229858A1 (en) 2009-03-25 2011-09-22 Los Alamos National Security, Llc Fiber optical assembly for fluorescence spectrometry
CN102365096A (zh) * 2009-03-25 2012-02-29 洛斯阿拉莫斯国家安全有限责任公司 传染剂的快速死前检测
TWI419711B (zh) * 2010-07-27 2013-12-21 Univ Nat Changhua Education Tyrosinase polypeptide inhibitor
CN102492018A (zh) * 2010-07-27 2012-06-13 萧乃文 酪氨酸酶多肽抑制剂
AU2012207454B2 (en) * 2011-01-18 2016-11-17 Prionics Ag Methods for amplification and detection of prions
CA2877505C (en) * 2012-06-12 2020-09-22 Helix Biopharma Corp. Antibodies and conjugates that target misfolded prion protein
US9809620B2 (en) 2013-04-30 2017-11-07 University Of Saskatchewan Prion disease-specific epitopes and methods of use thereof
CN108409865A (zh) * 2018-01-19 2018-08-17 鄞州出入境检验检疫局综合技术服务中心 特异性双酚a羊多克隆抗体及其应用
EP3966227A1 (de) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177754T1 (de) * 1991-12-03 1999-04-15 Proteus Molecular Design Fragmente von prion proteinen.
WO1993023432A1 (en) * 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
JP3495738B2 (ja) * 1995-09-14 2004-02-09 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 天然ＰｒＰｓｃ特異的抗体
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
EP0861900A1 (de) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunologischer Nachweis von Prionen
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies

Also Published As

Publication number Publication date
AU5637500A (en) 2001-01-09
EP1194164B1 (de) 2006-12-20
NZ516240A (en) 2005-11-25
MXPA01013186A (es) 2002-08-12
DE60032486T2 (de) 2007-08-16
WO2000078344A1 (en) 2000-12-28
HK1048955A1 (zh) 2003-04-25
JP2003521477A (ja) 2003-07-15
ATE348632T1 (de) 2007-01-15
WO2000078344A8 (en) 2001-11-15
EP1194164A1 (de) 2002-04-10
EP1194164B8 (de) 2007-03-21
AU783484B2 (en) 2005-11-03
ES2278617T3 (es) 2007-08-16
CA2377648A1 (en) 2000-12-28
CN1370078A (zh) 2002-09-18
EP1194164A4 (de) 2004-09-08

Similar Documents

Publication Publication Date Title
DE60032486D1 (de) Prion protein peptide und deren verwendung
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE507839T1 (de) Kombinationstherapie
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
ATE385806T1 (de) Fusionsproteine
ATE455561T1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
BR9707819A (pt) Imunogenos peptidicos
BRPI0413449A (pt) compostos de quinoxalina
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
PL1636261T3 (pl) Białka trombopoetynowe o ulepszonych właściwościach
TR199902866T2 (xx) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE528392T1 (de) Neues protein und dessen dns
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: IDEXX LABORATORIES, INC., WESTBROOK, ME., US

8363 Opposition against the patent
8365 Fully valid after opposition proceedings